GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Exelixis, Inc. (EXEL) [hlAlert]

Rating:
Buy EXEL
down 26.09 %

Exelixis, Inc. (EXEL) rated Buy with price target $11 by Maxim Group

Posted on: Tuesday,  Jan 21, 2014  9:25 AM ET by Maxim Group

Maxim Group rated Buy Exelixis, Inc. (NASDAQ: EXEL) on 01/21/2014, when the stock price was $8.24. Since
then, Exelixis, Inc. has lost 26.09% as of 08/27/2015's recent price of $6.09.
If you would have followed this Maxim Group's recommendation on EXEL, you would have lost 26.09% of your investment in 583 days.

Exelixis, Inc. (Exelixis) is developing therapies for cancer and other serious diseases. Through its drug discovery and development activities, the Company is building a portfolio of novel compounds. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease and various metabolic and cardiovascular disorders. Its most advanced pharmaceutical programs focus on drug discovery and development of small molecule drugs for cancer. The Company has nine compounds in clinical development: XL184, XL147, XL765, XL518, XL228, XL019, XL139, XL413 and XL888. Exelixis also has out-licensed to third parties for further development and commercialization of five compounds in preclinical and clinical development: XL880, XL281, XL652, XL550 and FXR Program. The Company has established commercial collaborations with several pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Genentech, Inc. and GlaxoSmithKline.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/21/2014 9:25 AM Buy
None
8.24 11.00
as of 10/17/2014
1 Week up  8.96 %
1 Month down  -7.05 %
3 Months down  -53.93 %
1 YTD down  -74.22 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/12/2013 9:25 AM Buy
None
5.00 7.50
5/28/2013 9:25 AM Hold
None
4.77 35.00
4/20/2012 8:25 AM Buy
None
4.77 9.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy